Synthetic protective effect of atorvastatin calcium on heart and kidney in patients with coronary heart disease complicating microalbuminuria
PENG Xue-mei
ZHANG Wu-ning
YU Ben-kai
GAO Xiao-dong
Abstract：Objective To observe the influences of atorvastatin calcium on blood fat and microalbuminuria (MAU) in patients with coronary heart disease (CHD). Methods The patients (n=80) with CHD complicating hyperlipidemia and MAU were chosen from the First Hospital of Beijing Fangshan District from Jan. 2012 to Jan. 2013. All patients were divided into 2 groups, and group A was treated with routine therapy of CHD and atorvastatin calcium (10 mg/d) and group B, routine therapy of CHD and atorvastatin calcium (20 mg/d). Before treatment and 12 months after treatment, the levels of blood fat [total cholesterol (TC), triglyceride (TG), low-density lipoprotein-cholesterol (LDL-C) and high-density lipoprotein-cholesterol (HDL-C)], MAU, incidence of major adverse cardiovascular events (MACE) during follow-up period, and incidence of adverse reactions (transaminase increasing, muscle pain and creatine phosphate kinase increasing) were observed in two groups. Results After treatment, the levels of TC, TG and LDL-C decreased and HDL-C level increased in two groups, which were more significant in group B [TC:(3.20±0.09) mmol/L vs. (4.21±0.37) mmol/L, TG:(1.73±0.21) mmol/L vs. (2.61± 0.73) mmol/L, LDL-C:(1.98±0.19) mmol/L vs. (2.07±0.29) mmol/L, HDL-C:(1.32±0.47) mmol/L vs. (1.12± 0.37) mmol/L]. MAU decreased also after treatment in two groups but the difference had no statistical significance between two groups [(44.30±3.84) mg/L vs. (42.10±5.65) mg/L]. During follow-up period, the incidence of MACE was lower in group B than that in group A (6.4%vs. 23.9%, P<0.01). There were no adverse reactions (muscle pain and creatine phosphate kinase increasing) observed. Conclusion Atorvastatin calcium can alleviate hyperlipidemia and MAU and improve prognosis in CHD patients. The higher the dose, the better the curative effect.
Keywords：Atorvastatin calciumCoronary heart diseaseHyperlipidemiaMicroalbuminuria
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 89-91 )